At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.
Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma
10th July 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now